Katie Ruch
Nurse Practitioner · Omaha, NENPI 1730312109
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (49.1%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. E.r. Squibb & Sons, L.L.C. accounts for 74.9% of it on its own, with 29 other manufacturers making up the rest. Reporting peaked in 2022 at $12,748 and has fallen 97.7% since, to $295 in 2025. Among nurse practitioner clinicians in NE with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 108 payments — averaging $242.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$20K
- Bristol Myers Squibb$3K
- Daiichi Sankyo Inc.$942
- AstraZeneca$600
- Janssen Scientific Affairs, LLC$455
- Incyte Corporation$345
- plus $1K from 24 others
What the payments were for
- Consulting fees$12,85549%
- Speaking & faculty fees$7,15127%
- Travel & lodging$2,79811%
- Food & beverage$3,27212%
- Education$1000%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 46 | $19,602 |
| Bristol Myers Squibb | 8 | $2,761 |
| Daiichi Sankyo Inc. | 9 | $942 |
| AstraZeneca | 1 | $600 |
| Janssen Scientific Affairs, LLC | 4 | $455 |
| Incyte Corporation | 3 | $345 |
| Johnson & Johnson | 3 | $272 |
| Seagen Inc. | 4 | $240 |
| Genentech, Inc. | 3 | $167 |
| AbbVie | 4 | $125 |
| Novocure Inc. | 1 | $125 |
| Lilly USA, LLC | 1 | $78 |
| Amgen | 3 | $77 |
| Regeneron Healthcare Solutions, Inc. | 2 | $73 |
| Accord Healthcare, Inc. | 1 | $66 |
| Merck | 1 | $23 |
| Novartis | 1 | $22 |
| Adaptive Biotechnologies Corporation | 1 | $21 |
| Tolmar, Inc. | 1 | $20 |
| Apellis Pharmaceuticals, Inc. | 1 | $19 |
| Boehringer Ingelheim | 1 | $18 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $18 |
| Pharmaessentia USA Corporation | 1 | $17 |
| CTI Biopharma Corp. | 1 | $16 |
| Genentech USA, Inc. | 1 | $14 |
| Jazz Pharmaceuticals Inc. | 1 | $14 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
| Recordati_rare_diseases_inc. | 1 | $13 |
| Pfizer | 1 | $13 |
| Clovis Oncology, Inc. | 1 | $5 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$26,175 in reported general payments places this provider in the 95th percentile of 924 nurse practitioner providers in Nebraska.
Other nurse practitioner in Omaha
- Kristen HammesOmaha$899K
- Amy MuchowiczOmaha$78K
- Kari CunninghamOmaha$53K
- Laura DonovanOmaha$49K
- Kathleen HealeyOmaha$36K
- Amanda GuggenmosOmaha$23K
- Amy YagerOmaha$15K
- Cara SchiesslerOmaha$14K
- Lindsay OneilOmaha$13K
- Beverly EverittOmaha$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.